Literature DB >> 24292993

Alterations in the levels of vesicular trafficking proteins involved in HIV replication in the brains and CSF of patients with HIV-associated neurocognitive disorders.

Jerel Fields1, Wilmar Dumaop, Anthony Adame, Ronald J Ellis, Scott Letendre, Igor Grant, Eliezer Masliah.   

Abstract

Human immunodeficiency virus (HIV) associated neurocognitive disorders (HAND) remain prevalent despite improved antiretroviral therapies. A HAND-specific biomarker indicative of neuropsychological impairment (NPI) would give insight into disease progression and aid clinicians in designing therapy. Endosomal sorting complex required for transport (ESCRT) proteins such as tumor susceptibility gene (TSG)-101, vacuolar protein sorting (VPS)-4 and LIP-5 are important for HIV replication and recently antiviral interferon stimulated gene (ISG)-15 was proposed as a biomarker for CNS injury. Here, we analyzed a well-characterized cohort of HIV+ cerebral spinal fluid (CSF) and postmortem brain specimens for multiple vesicular trafficking proteins and a related innate immune protein, ISG-15, TSG-101, VPS-4 and LIP-5. All protein levels trended higher with increased NPI and neuropathology. ISG-15 CSF levels were increased in HIV encephalitis (HIVE) compared to normal cases, and three quarters of HIVE samples had above average CSF ISG-15 levels. VPS-4 CSF levels were increased in NPI/NPI-O compared to normal patients. VPS-4 CSF levels in HIV-associated dementia were equivalent to that of normal patients. LIP-5 CSF levels positively correlate with ISG-15 levels, and higher than average ISG-15 levels indicate elevated viral load. Immunoblot and immunohistochemical analyses show increased expression of ISG-15, VPS-4 and LIP-5 in neuronal cell bodies and astroglial cells. ESCRT protein CSF levels analyzed in conjunction with viral load may be indicative of NPI stage, and may aid in the diagnosis and design of therapies for HIV patients. Further studies on the ESCRT protein expression during HIV infection may lead to a promising biomarker for predicting progression of NPI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24292993      PMCID: PMC3973444          DOI: 10.1007/s11481-013-9511-3

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  38 in total

Review 1.  Dynamics of ESCRT proteins.

Authors:  Nolwenn Jouvenet
Journal:  Cell Mol Life Sci       Date:  2012-06-06       Impact factor: 9.261

2.  Soluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected women.

Authors:  Yamil Gerena; Richard L Skolasky; Joyce M Velez; Dianedis Toro-Nieves; Raul Mayo; Avindra Nath; Valerie Wojna
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

3.  Mechanism of inhibition of retrovirus release from cells by interferon-induced gene ISG15.

Authors:  Zhizhou Kuang; Eun Joo Seo; Jonathan Leis
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy.

Authors:  Tanvi S Sharma; Denise L Jacobson; Lynn Anderson; Mariana Gerschenson; Russell B Van Dyke; Elizabeth J McFarland; Tracie L Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09       Impact factor: 2.205

5.  Interferon-stimulated gene 15 as a general marker for acute and chronic neuronal injuries.

Authors:  Ren-Gang Wang; Marcus Kaul; Dong-Xian Zhang
Journal:  Sheng Li Xue Bao       Date:  2012-10-25

6.  High interferon-stimulated gene ISG-15 expression affects HCV treatment outcome in patients co-infected with HIV and HCV.

Authors:  Antonios Katsounas; Jonathan J Hubbard; Crystal H Wang; Xiaozhen Zhang; Diana Dou; Bhavana Shivakumar; Sophie Winter; Joerg F Schlaak; Richard A Lempicki; Henry Masur; Michael Polis; Shyam Kottilil; Anu Osinusi
Journal:  J Med Virol       Date:  2013-06       Impact factor: 2.327

7.  Novel interactions of ESCRT-III with LIP5 and VPS4 and their implications for ESCRT-III disassembly.

Authors:  Soomin Shim; Samuel A Merrill; Phyllis I Hanson
Journal:  Mol Biol Cell       Date:  2008-04-02       Impact factor: 4.138

8.  Roles played by capsid-dependent induction of membrane curvature and Gag-ESCRT interactions in tetherin recruitment to HIV-1 assembly sites.

Authors:  Jonathan R Grover; G Nicholas Llewellyn; Ferri Soheilian; Kunio Nagashima; Sarah L Veatch; Akira Ono
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

9.  Reversing the Warburg effect as a treatment for glioblastoma.

Authors:  Ethan Poteet; Gourav Roy Choudhury; Ali Winters; Wenjun Li; Myoung-Gwi Ryou; Ran Liu; Lin Tang; Anuja Ghorpade; Yi Wen; Fang Yuan; Stephen T Keir; Hai Yan; Darell D Bigner; James W Simpkins; Shao-Hua Yang
Journal:  J Biol Chem       Date:  2013-02-13       Impact factor: 5.157

10.  The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment.

Authors:  Benjamin B Gelman; Tiansheng Chen; Joshua G Lisinicchia; Vicki M Soukup; J Russ Carmical; Jonathan M Starkey; Eliezer Masliah; Deborah L Commins; Dianne Brandt; Igor Grant; Elyse J Singer; Andrew J Levine; Jeremy Miller; Jessica M Winkler; Howard S Fox; Bruce A Luxon; Susan Morgello
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more
  8 in total

1.  The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.

Authors:  Jerel A Fields; Jeff Metcalf; Cassia Overk; Anthony Adame; Brian Spencer; Wolfgang Wrasidlo; Jazmin Florio; Edward Rockenstein; Johnny J He; Eliezer Masliah
Journal:  J Neurovirol       Date:  2017-01-19       Impact factor: 2.643

2.  Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.

Authors:  Wolf Wrasidlo; Leslie A Crews; Igor F Tsigelny; Emily Stocking; Valentina L Kouznetsova; Diana Price; Amy Paulino; Tania Gonzales; Cassia R Overk; Christina Patrick; Edward Rockenstein; Eliezer Masliah
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count.

Authors:  Radhika Adiga; Ahmet Y Ozdemir; Alexandra Carides; Melissa Wasilewski; William Yen; Pallavi Chitturi; Ronald Ellis; Dianne Langford
Journal:  J Neurovirol       Date:  2014-05-10       Impact factor: 2.643

4.  Biomarkers for NeuroAIDS: recent progress in the field.

Authors:  Howard S Fox
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-29       Impact factor: 4.147

5.  Curcumin improves synaptic plasticity impairment induced by HIV-1gp120 V3 loop.

Authors:  Ling-Ling Shen; Ming-Liang Jiang; Si-Si Liu; Min-Chun Cai; Zhong-Qiu Hong; Li-Qing Lin; Yan-Yan Xing; Gui-Lin Chen; Rui Pan; Li-Juan Yang; Ying Xu; Jun Dong
Journal:  Neural Regen Res       Date:  2015-06       Impact factor: 5.135

6.  Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats.

Authors:  Vez Repunte-Canonigo; Celine Lefebvre; Olivier George; Tomoya Kawamura; Marisela Morales; George F Koob; Andrea Califano; Eliezer Masliah; Pietro Paolo Sanna
Journal:  Mol Neurodegener       Date:  2014-07-01       Impact factor: 14.195

7.  ALV-J inhibits autophagy through the GADD45β/MEKK4/P38MAPK signaling pathway and mediates apoptosis following autophagy.

Authors:  Zhihong Liao; Xinheng Zhang; Cailiang Song; Wencheng Lin; Yuzhen Cheng; Zi Xie; Sheng Chen; Yu Nie; Aijun Li; Huanmin Zhang; Hongxin Li; Haiyun Li; Qingmei Xie
Journal:  Cell Death Dis       Date:  2020-08-12       Impact factor: 8.469

8.  Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.

Authors:  Jerel A Fields; Cassia Overk; Anthony Adame; Jazmin Florio; Michael Mante; Andrea Pineda; Paula Desplats; Edward Rockenstein; Cristian Achim; Eliezer Masliah
Journal:  J Neuroinflammation       Date:  2016-05-24       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.